Polyfunctional Fc-effector profiles mediated by IgG subclass selection distinguish RV144 and VAX003 vaccines

Science Translational Medicine

Volumn 6, Issue 228, 2014, Pages

  Chung, Amy W ^a   Ghebremichael, Musie ^a   Robinson, Hannah ^a   Brown, Eric ^b   Choi, Ickwon ^c   Lane, Sophie ^a   Dugast, Anne Sophie ^a   Schoen, Matthew K ^a   Rolland, Morgane ^d   Suscovich, Todd J ^a   Mahan, Alison E ^a   Liao, Larry ^e   Streeck, Hendrik ^d   Andrews, Charla ^d   Rerks Ngarm, Supachai ^f   Nitayaphan, Sorachai ^g   De Souza, Mark S ^g   Kaewkungwal, Jaranit ^h   Pitisuttithum, Punnee ^h   Francis, Donald ⁱ   Michael, Nelson L ^d   Kim, Jerome H ^d   Bailey Kellogg, Chris ^c   Ackerman, Margaret E ^b   Alter, Galit ^a   more..

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b DARTMOUTH COLLEGE   (United States)

^c Dartmouth Department of Computer Science_Dartmouth College   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f MINISTRY OF PUBLIC HEALTH   (Thailand)

^g ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^h MAHIDOL UNIVERSITY   (Thailand)

ⁱ Global Solutions for Infectious Diseases   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G3 ANTIBODY; IMMUNOGLOBULIN G4 ANTIBODY; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; UNCLASSIFIED DRUG; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DEPENDENT CELLULAR PHAGOCYTOSIS; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; BIOSYNTHESIS; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; PHYSIOLOGY;

AIDS VACCINES; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G;

EID: 84899105650     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3007736     Document Type: Article

References (41)

1. S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, J. Chiu, R. Paris, N. Premsri, C. Namwat, M. de Souza, E. Adams, M. Benenson, S. Gurunathan, J. Tartaglia, J. G. McNeil, D. P. Francis, D. Stablein, D. L. Birx, S. Chunsuttiwat, C. Khamboonruang, P. Thongcharoen, M. L. Robb, N. L. Michael, P. Kunasol, J. H. Kim; MOPH-TAVEG Investigators, Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220 (2009).
2. P. Pitisuttithum, P. Gilbert, M. Gurwith, W. Heyward, M. Martin, F. van Griensven, D. Hu, J. W. Tappero, K. Choopanya; Bangkok Vaccine Evaluation Group, Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194, 1661-1671 (2006).
3. P. Gilbert, M. Wang, T. Wrin, C. Petropoulos, M. Gurwith, F. Sinangil, P. D'Souza, I. R. Rodriguez-Chavez, A. DeCamp, M. Giganti, P. W. Berman, S. G. Self, D. C. Montefiori, Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccine. J. Infect. Dis. 202, 595-605 (2010).
4. B. M. McLellan JS, K. Hwang, H. Liao, S. Rerks-Ngarm, S. Nitayaphan, N. L. Michael, J. H. Kim, B. F. Haynes, L. Wang, P. D. Kwong, Structural and biophysical studies of antibodies isolated from RV144 vaccinees, paper presented at the Keystone Symposia: HIV Vaccines, Keystone, CO, 2012.
5. M. K. Gorny, R. Pan, C. Williams, X. H. Wang, B. Volsky, T. O'Neal, B. Spurrier, J. M. Sampson, L. Li, M. S. Seaman, X. P. Kong, S. Zolla-Pazner, Functional and immunochemical cross-reactivity of V2-specific monoclonal antibodies from HIV-1-infected individuals. Virology 427, 198-207 (2012).
6. D. C. Montefiori, C. Karnasuta, Y. Huang, H. Ahmed, P. Gilbert, M. S. de Souza, R. McLinden, S. Tovanabutra, A. Laurence-Chenine, E. Sanders-Buell, M. A. Moody, M. Bonsignori, C. Ochsenbauer, J. Kappes, H. Tang, K. Greene, H. Gao, C. C. LaBranche, C. Andrews, V. R. Polonis, S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, S. G. Self, P. W. Berman, D. Francis, F. Sinangil, C. Lee, J. Tartaglia, M. L. Robb, B. F. Haynes, N. L. Michael, J. H. Kim, Magnitude and breadth of the neutralizing antibody response in the RV144 and Vax003 HIV-1 vaccine efficacy trials. J. Infect. Dis. 206, 431-441 (2012).
7. N. G. Jones, A. DeCamp, P. Gilbert, M. L. Peterson, M. Gurwith, H. Cao, AIDSVAX immunization induces HIV-specific CD8+ T-cell responses in high-risk, HIV-negative volunteers who subsequently acquire HIV infection. Vaccine 27, 1136-1140 (2009).
8. B. F. Haynes, P. B. Gilbert, M. J. McElrath, S. Zolla-Pazner, G. D. Tomaras, S. M. Alam, D. T. Evans, D. C. Montefiori, C. Karnasuta, R. Sutthent, H. X. Liao, A. L. DeVico, G. K. Lewis, C. Williams, A. Pinter, Y. Fong, H. Janes, A. DeCamp, Y. Huang, M. Rao, E. Billings, N. Karasavvas, M. L. Robb, V. Ngauy, M. S. de Souza, R. Paris, G. Ferrari, R. T. Bailer, K. A. Soderberg, C. Andrews, P. W. Berman, N. Frahm, S. C. De Rosa, M. D. Alpert, N. L. Yates, X. Shen, R. A. Koup, P. Pitisuttithum, J. Kaewkungwal, S. Nitayaphan, S. Rerks-Ngarm, N. L. Michael, J. H. Kim, Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N. Engl. J. Med. 366, 1275-1286 (2012).
9. M. Rolland, P. T. Edlefsen, B. B. Larsen, S. Tovanabutra, E. Sanders-Buell, T. Hertz, A. C. deCamp, C. Carrico, S. Menis, C. A. Magaret, H. Ahmed, M. Juraska, L. Chen, P. Konopa, S. Nariya, J. N. Stoddard, K. Wong, H. Zhao, W. Deng, B. S. Maust, M. Bose, S. Howell, A. Bates, M. Lazzaro, A. O'Sullivan, E. Lei, A. Bradfield, G. Ibitamuno, V. Assawadarachai, R. J. O'Connell, M. S. deSouza, S. Nitayaphan, S. Rerks-Ngarm, M. L. Robb, J. S. McLellan, I. Georgiev, P. D. Kwong, J. M. Carlson, N. L. Michael, W. R. Schief, P. B. Gilbert, J. I. Mullins, J. H. Kim, Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2. Nature 490, 417-420 (2012).
10. M. E. Ackerman, A. S. Dugast, G. Alter, Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu. Rev. Med. 63, 113-130 (2012).
11. R. Jefferis, Isotype and glycoform selection for antibody therapeutics. Arch. Biochem. Biophys. 526, 159-166 (2012).
12. H. W. Schroeder Jr., L. Cavacini, Structure and function of immunoglobulins. J. Allergy Clin. Immunol. 125, S41-S52 (2010).
13. Z. Rozsnyay, G. Sármay, M. Walker, K. Maslanka, Z. Valasek, R. Jefferis, J. Gergely, Distinctive role of IgG1 and IgG3 isotypes in Fcg R-mediated functions. Immunology 66, 491-498 (1989).
14. P. W. Parren, P. A. Warmerdam, L. C. Boeije, J. Arts, N. A. Westerdaal, A. Vlug, P. J. Capel, L. A. Aarden, J. G. van de Winkel, On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2. J. Clin. Invest. 90, 1537-1546 (1992).
15. M. R. P. Edlefsen, M. Bonsignori, H.-X. Liao, B. Haynes, P. Gilbert, S. Rerks-Ngarm, N. Michael, J. Mullins, J. Kim, RV144 Sequencing Study Group, Sieve analysis and epitope mapping support anti-V2 antibody-mediated immune pressure of ALVAC-AIDSVAX vaccination in the RV144 trial, paper presented at the Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2012.
16. G. D. Tomaras, J. M. Binley, E. S. Gray, E. T. Crooks, K. Osawa, P. L. Moore, N. Tumba, T. Tong, X. Shen, N. L. Yates, J. Decker, C. K. Wibmer, F. Gao, S. M. Alam, P. Easterbrook, S. Abdool Karim, G. Kamanga, J. A. Crump, M. Cohen, G. M. Shaw, J. R. Mascola, B. F. Haynes, D. C. Montefiori, L. Morris, Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals. J. Virol. 85, 11502-11519 (2011).
17. R. M. Lynch, R. Rong, S. Boliar, A. Sethi, B. Li, J. Mulenga, S. Allen, J. E. Robinson, S. Gnanakaran, C. A. Derdeyn, The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J. Virol. 85, 905-915 (2011).
18. P. L. Moore, E. S. Gray, D. Sheward, M. Madiga, N. Ranchobe, Z. Lai, W. J. Honnen, M. Nonyane, N. Tumba, T. Hermanus, S. Sibeko, K. Mlisana, S. S. Abdool Karim, C. Williamson, A. Pinter, L. Morris; CAPRISA 002 Study, Potent and broad neutralization of HIV-1 subtype C by plasma antibodies targeting a quaternary epitope including residues in the V2 loop. J. Virol. 85, 3128-3141 (2011).
19. N. Karasavvas, E. Billings, M. Rao, C. Williams, S. Zolla-Pazner, R. T. Bailer, R. A. Koup, S. Madnote, D. Arworn, X. Shen, G. D. Tomaras, J. R. Currier, M. Jiang, C. Magaret, C. Andrews, R. Gottardo, P. Gilbert, T. J. Cardozo, S. Rerks-Ngarm, S. Nitayaphan, P. Pitisuttithum, J. Kaewkungwal, R. Paris, K. Greene, H. Gao, S. Gurunathan, J. Tartaglia, F. Sinangil, B. T. Korber, D. C. Montefiori, J. R. Mascola, M. L. Robb, B. F. Haynes, V. Ngauy, N. L. Michael, J. H. Kim, M. S. de Souza; MOPH TAVEG Collaboration, The Thai phase III HIV type 1 vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120. AIDS Res. Hum. Retroviruses 28, 1444-1457 (2012).
20. G. D. Tomaras, G. Ferrari, X. Shen, S. M. Alam, H. X. Liao, J. Pollara, M. Bonsignori, M. A. Moody, Y. Fong, X. Chen, B. Poling, C. O. Nicholson, R. Zhang, X. Lu, R. Parks, J. Kaewkungwal, S. Nitayaphan, P. Pitisuttithum, S. Rerks-Ngarm, P. B. Gilbert, J. H. Kim, N. L. Michael, D. C. Montefiori, B. F. Haynes, Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc. Natl. Acad. Sci. U.S.A. 110, 9019-9024 (2013).
21. R. Jefferis, Antibody therapeutics: Isotype and glycoform selection. Expert Opin. Biol. Ther. 7, 1401-1413 (2007).
22. P. Karagiannis, A. E. Gilbert, D. H. Josephs, N. Ali, T. Dodev, L. Saul, I. Correa, L. Roberts, E. Beddowes, A. Koers, C. Hobbs, S. Ferreira, J. L. Geh, C. Healy, M. Harries, K. M. Acland, P. J. Blower, T. Mitchell, D. J. Fear, J. F. Spicer, K. E. Lacy, F. O. Nestle, S. N. Karagiannis, IgG4 subclass antibodies impair antitumor immunity in melanoma. J. Clin. Invest. 123, 1457-1474 (2013).
23. A. Nirula, S. M. Glaser, S. L. Kalled, F. R. Taylor, What is IgG4? A review of the biology of a unique immunoglobulin subtype. Curr. Opin. Rheumatol. 23, 119-124 (2011).
24. H. Groux, J. Gysin, Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum : Functional role of IgG subclasses. Res. Immunol. 141, 529-542 (1990).
25. J. S. Richards, D. I. Stanisic, F. J. Fowkes, L. Tavul, E. Dabod, J. K. Thompson, S. Kumar, C. E. Chitnis, D. L. Narum, P. Michon, P. M. Siba, A. F. Cowman, I. Mueller, J. G. Beeson, Association between naturally acquired antibodies to erythrocyte-binding antigens of Plasmodium falciparum and protection from malaria and high-density parasitemia. Clin. Infect. Dis. 51, e50-e60 (2010).
26. M. D. Segeja, B. P. Mmbando, M. D. Seth, J. P. Lusingu, M. M. Lemnge, Acquisition of antibodies to merozoite surface protein 3 among residents of Korogwe, north eastern Tanzania. BMC Infect. Dis. 10, 55 (2010).
27. D. N. Forthal, G. Landucci, H. Ding, J. C. Kappes, A. Wang, I. Thung, T. Phan, IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 25, 2099-2104 (2011).
28. W. van de Veen, B. Stanic, G. Yaman, M. Wawrzyniak, S. Söllner, D. G. Akdis, B. Rückert, C. A. Akdis, M. Akdis, IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J. Allergy Clin. Immunol. 131, 1204-1212 (2013).
29. K. Kinoshita, J. Tashiro, S. Tomita, C. G. Lee, T. Honjo, Target specificity of immunoglobulin class switch recombination is not determined by nucleotide sequences of S regions. Immunity 9, 849-858 (1998).
30. J. Banchereau, D. Blanchard, F. Brière, J. P. Galizzi, P. Garrone, P. Hermann, S. Lebecque, F. Rousset, Role of cytokines in human B lymphocyte growth and differentiation. Nouv. Rev. Fr. Hematol. 35, 61-66 (1993).
31. G. D. Tomaras, N. L. Yates, P. Liu, L. Qin, G. G. Fouda, L. L. Chavez, A. C. Decamp, R. J. Parks, V. C. Ashley, J. T. Lucas, M. Cohen, J. Eron, C. B. Hicks, H. X. Liao, S. G. Self, G. Landucci, D. N. Forthal, K. J. Weinhold, B. F. Keele, B. H. Hahn, M. L. Greenberg, L. Morris, S. S. Karim, W. A. Blattner, D. C. Montefiori, G. M. Shaw, A. S. Perelson, B. F. Haynes, Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82, 12449-12463 (2008).
32. P. J. Cooper, I. Espinel, M. Wieseman, W. Paredes, M. Espinel, R. H. Guderian, T. B. Nutman, Human onchocerciasis and tetanus vaccination: Impact on the postvaccination antitetanus antibody response. Infect. Immun. 67, 5951-5957 (1999).
33. E. van Riet, K. Retra, A. A. Adegnika, C. M. Jol-van der Zijde, H. W. Uh, B. Lell, S. Issifou, P. G. Kremsner, M. Yazdanbakhsh, M. J. van Tol, F. C. Hartgers, Cellular and humoral responses to tetanus vaccination in Gabonese children. Vaccine 26, 3690-3695 (2008).
34. M. E. Ackerman, M. Crispin, X. Yu, K. Baruah, A. W. Boesch, D. J. Harvey, A. S. Dugast, E. L. Heizen, A. Ercan, I. Choi, H. Streeck, P. A. Nigrovic, C. Bailey-Kellogg, C. Scanlan, G. Alter, Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J. Clin. Invest. 123, 2183-2192 (2013).
35. J. G. Flanagan, T. H. Rabbitts, Arrangement of human immunoglobulin heavy chain constant region genes implies evolutionary duplication of a segment containing γ, ε and α genes. Nature 300, 709- 713 (1982).
36. N. L. Yates, H. X. Liao, Y. Fong, A. deCamp, N. A. Vandergrift, W. T. Williams, S. M. Alam, G. Ferrari, Z. Yang, K. E. Seaton, P. W. Berman, M. D. Alpert, D. T. Evans, L. Y. O'Connell, D. Francis, F. Sinangil, C. Lee, S. Nitayaphan, S. Rerks-Ngarm, J. Kaewkungwal, P. Pitisuttithum, J. Tartaglia, A. Pinter, S. Zolla-Pazner, P. B. Gilbert, G. J. Nabel, N. L. Michael, J. H. Kim, D. C. Montefiori, B. F. Haynes, G. D. Tomaras, Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination. Sci. Transl. Med. 6, 228ra39 (2014)
37. M. E. Ackerman, B. Moldt, R. T. Wyatt, A. S. Dugast, E. McAndrew, S. Tsoukas, S. Jost, C. T. Berger, G. Sciaranghella, Q. Liu, D. J. Irvine, D. R. Burton, G. Alter, A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8-19 (2011).
38. H1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat. Med. 13, 843-850 (2007).
39. V. R. Gómez-Román, R. H. Florese, L. J. Patterson, B. Peng, D. Venzon, K. Aldrich, M. Robert-Guroff, A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J. Immunol. Methods 308, 53-67 (2006).
40. A. W. Chung, E. Rollman, R. J. Center, S. J. Kent, I. Stratov, Rapid degranulation of NK cells following activation by HIV-specific antibodies. J. Immunol. 182, 1202-1210 (2009).
41. E. P. Brown, A. F. Licht, A. S. Dugast, I. Choi, C. Bailey-Kellogg, G. Alter, M. E. Ackerman, High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386, 117-123 (2012).